<?xml version="1.0" encoding="UTF-8"?>
<p id="Par48">U.S. FDA approved zanamivir for use as a dry powder in children aged 5–7 years and old age individuals for management as well as prophylaxis of influenza type A or B virus. According to 74 observational studies this drug is beneficial for the reduction of mortality and influenza-related complications [
 <xref ref-type="bibr" rid="CR82">82</xref>]. However, its use is limited to individuals with chronic pulmonary diseases such as asthma. Subsequently, two other classes of NA inhibitor drugs were identified for the management of influenza A and B infections [
 <xref ref-type="bibr" rid="CR83">83</xref>]. On the other hand, their use is limited to a few countries, including Japan, China, South Korea and the USA [
 <xref ref-type="bibr" rid="CR84">84</xref>, 
 <xref ref-type="bibr" rid="CR85">85</xref>].
</p>
